Kiniksa(KNSA) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - ARCALYST product revenue grew 65% year-over-year to $202.1 million in Q4 2025, and 62% to $677.6 million for the full year 2025 [5][17] - Net income was $14.2 million in Q4 2025, compared to a net loss of $8.9 million in Q4 2024, and net income for the full year 2025 was $59 million, compared to a net loss of $43.2 million for the full year 2024 [17][18] - Cash at the end of 2025 was $414.1 million, representing $170.4 million of net cash generation for the year [19] Business Line Data and Key Metrics Changes - The primary driver of revenue growth was the expanding adoption of interleukin-1 alpha and beta inhibition with ARCALYST as a second-line treatment [9] - The average total duration of therapy for ARCALYST is approaching three years, with robust payer approval rates and strong patient adherence [12] Market Data and Key Metrics Changes - At the end of 2025, ARCALYST had over 4,150 prescribers, with around 29% prescribing for two or more recurrent pericarditis patients [11] - Penetration into the two-plus recurrence target market increased to approximately 18% at the end of 2025, compared to around 15% in mid-2025 and 13% at the end of 2024 [13] Company Strategy and Development Direction - The company aims to unlock the next phase of growth for ARCALYST by driving further physician awareness and advancing digital marketing initiatives [11] - KPL-387 is expected to address key patient needs and expand market penetration by potentially enabling monthly dosing with an auto-injector [7][54] - The company is focused on both ARCALYST and advancing its clinical portfolio to bring additional therapies to patients suffering from debilitating diseases [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of ARCALYST and the potential for KPL-387 to capture additional market share [5][9] - The company is optimistic about the future, emphasizing the importance of ongoing investments in R&D and commercialization efforts [6][20] Other Important Information - The company reported that ARCALYST revenue growth has been profitable since Q4 2021, allowing for strategic investments in sales and marketing [6] - The company expects to remain cash flow positive on an annual basis under its current operating plan [19] Q&A Session Summary Question: What do you think the peak penetration is for ARCALYST in the multiple recurrent setting? - Management has not commented on peak penetration but believes there is significant growth potential remaining [23] Question: Is the pace of growth in first recurrence versus multiple recurrence patients the same? - The percentage of first recurrence patients has grown, and management views this as a positive change as physicians become more comfortable prescribing ARCALYST [29] Question: What is the extent of FDA interactions for KPL-387? - The company values its interactions with the FDA and has laid out a comprehensive development program for KPL-387 [38] Question: Are there differences in persistence rates between first recurrence and multiple recurrence populations? - No meaningful differences in persistence rates have been observed between the two populations [40] Question: How are you thinking about the enrollment curve for the phase III study of KPL-387? - Data from the Phase II portion of the trial is expected in the second half of 2026, with plans for a phase III study thereafter [46]